LIVIVO - Search results -

Search results

Result 1 - 10 of total 101

Search options

Article ; Online: Peran lingkungan keluarga dalam mengembangkan wirausaha muda

Khofifatu Rohmah Adi / Idris Idris

Jurnal Teori dan Praksis Pembelajaran IPS, Vol 6, Iss 1, Pp 1-

2021 Volume 8

Abstract: The development and maturity of a person's business is influenced by many factors. Many factors also influence the development of pilot businesses that are started and carried out by students. One of the factors that play an essential role in influencing ...

Abstract	The development and maturity of a person's business is influenced by many factors. Many factors also influence the development of pilot businesses that are started and carried out by students. One of the factors that play an essential role in influencing young entrepreneurs can come from their parents or family environment. This article aims to identify and how the family's role in motivating and developing young entrepreneurs' potential. This research is a qualitative descriptive study. In-depth interviews carried out data collection. The data obtained were then analyzed using interactive analysis techniques, which consisted of 4 stages: data collection, data reduction, data presentation, and concluding. The results showed that entrepreneurial students who had sufficiently developed businesses received much support from their families. Parents' role as a form of support for their children in entrepreneurship is social, instrumental, emotional, and other support. The concrete form of this support is supported in providing facilities for business development, accompanying and assisting the business carried out by their children, giving permission and trust in children. These results can be used as knowledge and input to parents about how they should support children in entrepreneurship. DOI: http://dx.doi.org/10.17977/um022v6i12021p1
Keywords	parents' role ; young entrepreneur ; Theory and practice of education ; LB5-3640 ; Social Sciences ; H
Subject code	360
Language	Indonesian
Publishing date	2021-04-01T00:00:00Z
Publisher	Prodi Pendidikan IPS Fakultas Ilmu Sosial Universitas Negeri Malang
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: The presence of multidrug-resistant staphylococcal isolates outside of a major hospital in London, United Kingdom.

Idris, Adi / Cutler, Ron R

Central European journal of public health

2020 Volume 27, Issue 4, Page(s) 340–344

Abstract: Objective: Drug-resistant staphylococci have been a growing threat to the community and hospitals due to the misuse of antibiotics by humans, industrialisation and lack of novel antimicrobials currently available. Little is known about the prevalence of ...

Abstract	Objective: Drug-resistant staphylococci have been a growing threat to the community and hospitals due to the misuse of antibiotics by humans, industrialisation and lack of novel antimicrobials currently available. Little is known about the prevalence of drug-resistant staphylococci in non-healthcare environments outside hospitals in the London area. Staphylococci can spread via contact with contaminated objects. Traffic light buttons present a fast and easy transmission route for staphylococci. Methods: Traffic light buttons outside a major hospital in London were swabbed and cultured onto selective media to isolate staphylococci bacteria before performing antimicrobial susceptibility testing on the isolates. The identity of the isolates were determined using MALDI-TOF mass spectrometry (MS). Staphylococci isolates resistant to oxacillin were further tested for minimum inhibitory concentration (MIC). PCR analysis of the mecA gene, a gene that confers resistance to oxacillin, is used to determine the level of resistance to oxacillin. Results: Eight different staphylococcal species were identified by MALDI-TOF-MS analysis. Out of the 66 staphylococci isolates, 16 were resistant to multiple antibiotics including six isolates which were oxacillin resistant. Conclusion: This work provides evidence of the presence of multidrug-resistant staphylococci in the vicinity of the hospital environment in London.
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Drug Resistance, Multiple ; Hospitals ; Humans ; London ; Microbial Sensitivity Tests ; Oxacillin/pharmacology ; Staphylococcus/drug effects ; Staphylococcus/isolation & purification
Chemical Substances	Anti-Bacterial Agents ; Oxacillin (UH95VD7V76)
Language	English
Publishing date	2020-01-24
Publishing country	Czech Republic
Document type	Journal Article
ZDB-ID	1176053-9
ISSN	1803-1048 ; 1210-7778 ; 0022-1732
ISSN (online)	1803-1048
ISSN	1210-7778 ; 0022-1732
DOI	10.21101/cejph.a5000
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4008: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity.

Idris, Adi / Supramaniam, Aroon / Tayyar, Yaman / Kelly, Gabrielle / McMillan, Nigel A J / Morris, Kevin V

Antiviral research

2024 Volume 222, Page(s) 105815

Abstract: There remains a striking overall mortality burden of COVID-19 worldwide. Given the waning effectiveness of current SARS-CoV-2 antivirals due to the rapid emergence of new variants of concern (VOC), we employed a direct-acting molecular therapy approach ... ...

Abstract	There remains a striking overall mortality burden of COVID-19 worldwide. Given the waning effectiveness of current SARS-CoV-2 antivirals due to the rapid emergence of new variants of concern (VOC), we employed a direct-acting molecular therapy approach using gene silencing RNA interference (RNAi) technology. In this study, we developed and screened several ultra-conserved small-interfering RNAs (siRNAs) before selecting one potent siRNA candidate for pre-clinical in vivo testing. This non-immunostimulatory, anti-SARS-CoV-2 siRNA candidate maintains its antiviral activity against all tested SARS-CoV-2 VOC and works effectively as a single agent. For the first time, significant antiviral effects in both the lungs and nasal cavities of SARS-CoV-2 infected mice were observed when this siRNA candidate was delivered intranasally (IN) as a prophylactic agent with the aid of lipid nanoparticles (LNPs). Importantly, a pre-exposure prophylactic IN-delivered anti-SARS-CoV-2 siRNA antiviral that can ameliorate viral replication in the nasal cavity could potentially prevent aerosol spread of respiratory viruses. An IN delivery approach would allow for the development of a direct-acting nasal spray approach that could be self-administered prophylactically.
MeSH term(s)	Animals ; Mice ; RNA, Small Interfering/genetics ; COVID-19/prevention & control ; Nasal Cavity ; SARS-CoV-2/genetics ; Antiviral Agents/therapeutic use ; Lung
Chemical Substances	RNA, Small Interfering ; Antiviral Agents
Language	English
Publishing date	2024-01-19
Publishing country	Netherlands
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	306628-9
ISSN	1872-9096 ; 0166-3542
ISSN (online)	1872-9096
ISSN	0166-3542
DOI	10.1016/j.antiviral.2024.105815
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1627: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Extracellular Vesicles Loaded with Long Antisense RNAs Repress Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Idris, Adi / Shrivastava, Surya / Supramaniam, Aroon / Ray, Roslyn M / Shevchenko, Galina / Acharya, Dhruba / McMillan, Nigel A J / Morris, Kevin V

Nucleic acid therapeutics

2024

Abstract: Long antisense RNAs (asRNAs) have been observed to repress HIV and other virus expression in a manner that is refractory to viral evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 ...

Abstract	Long antisense RNAs (asRNAs) have been observed to repress HIV and other virus expression in a manner that is refractory to viral evolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) disease, has a distinct ability to evolve resistance around antibody targeting, as was evident from the emergence of various SARS-CoV-2 spike antibody variants. Importantly, the effectiveness of current antivirals is waning due to the rapid emergence of new variants of concern, more recently the omicron variant. One means of avoiding the emergence of viral resistance is by using long asRNA to target SARS-CoV-2. Similar work has proven successful with HIV targeting by long asRNA. In this study, we describe a long asRNA targeting SARS-CoV-2 RNA-dependent RNA polymerase gene and the ability to deliver this RNA in extracellular vesicles (EVs) to repress virus expression. The observations presented in this study suggest that EV-delivered asRNAs are one means to targeting SARS-CoV-2 infection, which is both effective and broadly applicable as a means to control viral expression in the absence of mutation. This is the first demonstration of the use of engineered EVs to deliver long asRNA payloads for antiviral therapy.
Language	English
Publishing date	2024-03-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	2639888-6
ISSN	2159-3345 ; 2159-3337
ISSN (online)	2159-3345
ISSN	2159-3337
DOI	10.1089/nat.2023.0078
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Analysis of a hit-and-run tumor model by HPV in oropharyngeal cancers.

Ferreira, Danyelle Assis / Idris, Adi / McMillan, Nigel A J

Journal of medical virology

2022 Volume 95, Issue 1, Page(s) e28260

Abstract: Several viruses are known to be associated with the development of certain cancers, including human papilloma virus (HPV), an established causative agent for a range of anogenital and head and neck cancers. However, the causality has been based on the ... ...

Abstract	Several viruses are known to be associated with the development of certain cancers, including human papilloma virus (HPV), an established causative agent for a range of anogenital and head and neck cancers. However, the causality has been based on the presence of the virus, or its genetic material, in the sampled tumors. We have long wondered if viruses cause cancer via a "hit and run" mechanism such that they are no longer present in the resulting tumors. Here, we hypothesize that the absence of viral genes from the tumor does not necessarily exclude the viral aetiology. To test this, we used an HPV-driven oropharyngeal cancer (OPC) tumor model and CRISPR to delete the viral oncogene, E7. Indeed, the genetic removal of HPV E7 oncogene eliminates tumors in vivo. Remarkably, E7 deleted tumors recurred over time and develop new mutations not previously seen in HPV
MeSH term(s)	Humans ; Human Papillomavirus Viruses ; Oncogene Proteins, Viral/genetics ; Papillomavirus Infections/pathology ; Repressor Proteins/genetics ; Neoplasm Recurrence, Local ; Oropharyngeal Neoplasms/complications ; Oropharyngeal Neoplasms/pathology ; Head and Neck Neoplasms ; Papillomavirus E7 Proteins/genetics
Chemical Substances	Oncogene Proteins, Viral ; Repressor Proteins ; Papillomavirus E7 Proteins
Language	English
Publishing date	2022-11-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	752392-0
ISSN	1096-9071 ; 0146-6615
ISSN (online)	1096-9071
ISSN	0146-6615
DOI	10.1002/jmv.28260
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1320: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: RNAi to treat SARS-CoV-2-variant proofing the next generation of therapies.

McMillan, Nigel A J / Morris, Kevin V / Idris, Adi

EMBO molecular medicine

2022 Volume 14, Issue 4, Page(s) e15811

Abstract: There is an urgent need to bring new antivirals to SARS-CoV-2 to the market. Indeed, in the last 3 months, we have seen at least two new antivirals approved, molnupiravir and paxlovid. Both are older established antivirals that show some efficacy against ...

Abstract	There is an urgent need to bring new antivirals to SARS-CoV-2 to the market. Indeed, in the last 3 months, we have seen at least two new antivirals approved, molnupiravir and paxlovid. Both are older established antivirals that show some efficacy against SARS-CoV-2. The work by Chang et al (2022) in the current issue of EMBO Molecular Medicine explores the use of short interfering RNAs to directly target SARS-CoV-2 and shows that RNAi is an effective approach to reducing, or even eliminating viral replication, depending on the experimental setting. This antiviral effect results in significant prevention of infection-related pathology in animals. The key feature of this approach, besides its simplicity as naked siRNAs, is that all current variants are covered by this treatment.
MeSH term(s)	Animals ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19/therapy ; RNA Interference ; RNA, Small Interfering/genetics ; RNA, Small Interfering/pharmacology ; RNA, Small Interfering/therapeutic use ; SARS-CoV-2/genetics ; Virus Replication
Chemical Substances	Antiviral Agents ; RNA, Small Interfering
Language	English
Publishing date	2022-03-14
Publishing country	England
Document type	Journal Article
ZDB-ID	2467145-9
ISSN	1757-4684 ; 1757-4676
ISSN (online)	1757-4684
ISSN	1757-4676
DOI	10.15252/emmm.202215811
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6784: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genetic deletion of HPV E7 oncogene effectively regresses HPV driven oral squamous carcinoma tumour growth.

Ferreira, Danyelle Assis / McMillan, Nigel A J / Idris, Adi

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2022 Volume 155, Page(s) 113782

Abstract: The major HPV oncogenes, E6 and E7, are known for its notoriety in driving the carcinogenic process in human papilloma virus (HPV) driven cancers. It is well-established that the removal of E7 dampens HPV cancer cell growth and proliferation. This has ... ...

Abstract	The major HPV oncogenes, E6 and E7, are known for its notoriety in driving the carcinogenic process in human papilloma virus (HPV) driven cancers. It is well-established that the removal of E7 dampens HPV cancer cell growth and proliferation. This has made E7 an attractive target for HPV cancers. Seminal work from our laboratory employed a CRISPR editing approach to delete E7 which resulted in the effective elimination of HPV
MeSH term(s)	Female ; Humans ; Papillomaviridae/genetics ; Alphapapillomavirus/genetics ; Uterine Cervical Neoplasms/drug therapy ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/pathology ; Papillomavirus E7 Proteins/genetics ; Oncogene Proteins, Viral/genetics ; Papillomavirus Infections/pathology ; Carcinoma, Squamous Cell/drug therapy ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/pathology ; Mouth Neoplasms/drug therapy ; Mouth Neoplasms/genetics ; Oncogenes ; Aurora Kinases
Chemical Substances	Papillomavirus E7 Proteins ; Oncogene Proteins, Viral ; Aurora Kinases (EC 2.7.11.1)
Language	English
Publishing date	2022-09-30
Publishing country	France
Document type	Journal Article
ZDB-ID	392415-4
ISSN	1950-6007 ; 0753-3322 ; 0300-0893
ISSN (online)	1950-6007
ISSN	0753-3322 ; 0300-0893
DOI	10.1016/j.biopha.2022.113782
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recent advances in the development of sialyltransferase inhibitors to control cancer metastasis: A comprehensive review.

Al Saoud, Ranim / Hamrouni, Amar / Idris, Adi / Mousa, Walaa K / Abu Izneid, Tareq

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2023 Volume 165, Page(s) 115091

Abstract: Metastasis accounts for the majority of cancer-associated mortalities, representing a huge health and economic burden. One of the mechanisms that enables metastasis is hypersialylation, characterized by an overabundance of sialylated glycans on the tumor ...

Abstract	Metastasis accounts for the majority of cancer-associated mortalities, representing a huge health and economic burden. One of the mechanisms that enables metastasis is hypersialylation, characterized by an overabundance of sialylated glycans on the tumor surface, which leads to repulsion and detachment of cells from the original tumor. Once the tumor cells are mobilized, sialylated glycans hijack the natural killer T-cells through self-molecular mimicry and activatea downstream cascade of molecular events that result in inhibition of cytotoxicity and inflammatory responses against cancer cells, ultimately leading to immune evasion. Sialylation is mediated by a family of enzymes known as sialyltransferases (STs), which catalyse the transfer of sialic acid residue from the donor, CMP-sialic acid, onto the terminal end of an acceptor such as N-acetylgalactosamine on the cell-surface. Upregulation of STs increases tumor hypersialylation by up to 60% which is considered a distinctive hallmark of several types of cancers such as pancreatic, breast, and ovarian cancer. Therefore, inhibiting STs has emerged as a potential strategy to prevent metastasis. In this comprehensive review, we discuss the recent advances in designing novel sialyltransferase inhibitors using ligand-based drug design and high-throughput screening of natural and synthetic entities, emphasizing the most successful approaches. We analyse the limitations and challenges of designing selective, potent, and cell-permeable ST inhibitors that hindered further development of ST inhibitors into clinical trials. We conclude by analysing emerging opportunities, including advanced delivery methods which further increase the potential of these inhibitors to enrich the clinics with novel therapeutics to combat metastasis.
MeSH term(s)	Humans ; N-Acetylneuraminic Acid/therapeutic use ; Neoplasms/drug therapy ; Cytidine Monophosphate N-Acetylneuraminic Acid ; Polysaccharides/therapeutic use ; Sialyltransferases
Chemical Substances	N-Acetylneuraminic Acid (GZP2782OP0) ; Cytidine Monophosphate N-Acetylneuraminic Acid (3063-71-6) ; Polysaccharides ; Sialyltransferases (EC 2.4.99.-)
Language	English
Publishing date	2023-07-06
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	392415-4
ISSN	1950-6007 ; 0753-3322 ; 0300-0893
ISSN (online)	1950-6007
ISSN	0753-3322 ; 0300-0893
DOI	10.1016/j.biopha.2023.115091
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Human papillomavirus and Epstein-Barr virus co-infection in oral and oropharyngeal squamous cell carcinomas: A systematic review and meta-analysis.

Rahman, Rifat / Shaikh, Mushfiq H / Gopinath, Divya / Idris, Adi / Johnson, Newell W

Molecular oral microbiology

2023 Volume 38, Issue 4, Page(s) 259–274

Abstract: Squamous cell carcinoma of the oral cavity (OSCC) is the most common head-and-neck malignancy. Importantly, we are experiencing an alarming rise in the incidence of oropharyngeal squamous cell carcinoma (OPSCC) globally. Oncogenic viruses, human ... ...

Abstract	Squamous cell carcinoma of the oral cavity (OSCC) is the most common head-and-neck malignancy. Importantly, we are experiencing an alarming rise in the incidence of oropharyngeal squamous cell carcinoma (OPSCC) globally. Oncogenic viruses, human papillomavirus (HPV) and Epstein-Barr virus (EBV), are known to be co-associated with OSCC and OPSCC cases. However, the reported incidence of HPV and EBV co-infection in OSCCs and OPSCCs globally is unknown. To address this, we performed a formal meta-analysis and systematic review on published studies that report the detection of both EBV and HPV in OSCCs and OPSCCs. Our analysis revealed 18 relevant studies out of a total of 1820 cases (1181 from the oral cavity and 639 from the oropharynx). Overall, HPV and EBV co-infection was found in 11.9% of OSCC and OPSCC cases combined (95% CI: 8%-14.1%). Based on anatomical subsite, dual positivity estimates were 10.5% (95% CI: 6.7%-15.1%) for OSCC and 14.2% (95% CI: 9.1%-21.3%) for OPSCC. The highest dual positivity rates described were in European countries: for OSCC 34.7% (95% CI: 25.9%-44.6%) in Sweden and for OPSCC, 23.4% (95% CI: 16.9%-31.5%) in Poland. Given these substantive prevalence rates, the value of detecting dual infection in the diagnosis and prognosis of these cancers deserves careful longitudinal studies, as do implications for cancer prevention and therapy. We further proposed molecular mechanisms that could explain how HPV and EBV could co-contribute to the aetiology of OSCCs and OPSCCs.
MeSH term(s)	Humans ; Squamous Cell Carcinoma of Head and Neck/epidemiology ; Squamous Cell Carcinoma of Head and Neck/complications ; Epstein-Barr Virus Infections/complications ; Epstein-Barr Virus Infections/diagnosis ; Epstein-Barr Virus Infections/epidemiology ; Herpesvirus 4, Human ; Human Papillomavirus Viruses ; Papillomavirus Infections/diagnosis ; Papillomavirus Infections/epidemiology ; Papillomavirus Infections/complications ; Coinfection/epidemiology ; Coinfection/complications ; Head and Neck Neoplasms/complications
Language	English
Publishing date	2023-04-15
Publishing country	Denmark
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Review
ZDB-ID	2537726-7
ISSN	2041-1014 ; 2041-1006
ISSN (online)	2041-1014
ISSN	2041-1006
DOI	10.1111/omi.12412
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2199: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hyperactivating p53 in Human Papillomavirus-Driven Cancers: A Potential Therapeutic Intervention.

Idres, Yusuf M / McMillan, Nigel A J / Idris, Adi

Molecular diagnosis & therapy

2022 Volume 26, Issue 3, Page(s) 301–308

Abstract: Despite a vaccine being available, human papillomavirus virus (HPV)-driven cancers remain the ninth most prevalent cancers globally. Current therapies have significant drawbacks and often still lead to poor prognosis and underwhelming survival rates. ... ...

Abstract	Despite a vaccine being available, human papillomavirus virus (HPV)-driven cancers remain the ninth most prevalent cancers globally. Current therapies have significant drawbacks and often still lead to poor prognosis and underwhelming survival rates. With gene therapy becoming more available in the clinic, it poses a new front for therapeutic development. A characteristic of HPV-driven cancers is the ability to encode oncoproteins that aberrate normal p53 function without mutating this tumour-suppressor gene. The HPV E6 oncoprotein degrades p53 to allow the HPV-driven carcinogenic process to proceed. This review aimed to investigate the use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) gene-editing technology and how it may be used to overcome HPV-mediated silencing of p53 by hyper-expressing the p53 promoter. Increasing p53 bioavailability may have promising potential as a therapy and has been a goal in the context of HPV-driven cancers. Clinical trials and proof-of-concept pre-clinical work have shown positive outcomes and tumour death when p53 levels are increased. Despite previous successes of RNA-based medicines, including the knockout of HPV oncogenes, the use of CRISPR activation is yet to be investigated as a promising potential therapy. This short review summarises key developments on attempts that have been made to increase p53 expression in the context of HPV cancer therapy, but leaves open the possibility for other cancers bearing a p53 wild-type gene.
MeSH term(s)	Alphapapillomavirus/genetics ; Alphapapillomavirus/metabolism ; Female ; Humans ; Oncogene Proteins, Viral/genetics ; Oncogene Proteins, Viral/metabolism ; Papillomaviridae/genetics ; Papillomaviridae/metabolism ; Papillomavirus Infections/complications ; Papillomavirus Infections/genetics ; Repressor Proteins/genetics ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism ; Uterine Cervical Neoplasms/genetics
Chemical Substances	Oncogene Proteins, Viral ; Repressor Proteins ; Tumor Suppressor Protein p53
Language	English
Publishing date	2022-04-05
Publishing country	New Zealand
Document type	Journal Article ; Review
ZDB-ID	2232796-4
ISSN	1179-2000 ; 1177-1062
ISSN (online)	1179-2000
ISSN	1177-1062
DOI	10.1007/s40291-022-00583-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5202: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito